Drug induced host factors which stimulate growth of residual leukemia in Lewis x brown Norway F1 (LEW-BN) rats

P. J. Burke, Judith Karp, P. L. Saylor

Research output: Contribution to journalArticle

Abstract

Antitumor synergism occurs with two drugs in sequence when the second drug is given at the time of maximal regrowth of residual leukemia and peak humoral stimulatory activity (HSA). To determine if this enhancement relates to a host derived HSA, studies were conducted in Lewis x brown Norway F1 rats bearing brown Norway myelocytic leukemia. A significant cure rate was observed in rats treated initially with 1-β-D-arabinofuranosylcytosine and then given injections of 106 leukemia cells and treated with a second 2-day course of 1-β-D-arabinofuranosyl-cytosine in every-8-h s.c. injections in the 6-day period after the initial drug. No effect on survival of the initial drug or of the second drug given at intervals after day 6 was noted. This result is consistent with the efficacy of treatment at the time of peak HSA and tumor growth. The direct effect of HSA on tumor sensitivity to 1-β-D-arabinofuranosylcytosine was evaluated by 18-h incubations of leukemia and HSA, followed by bioassay. Increased survival and high cure rates were observed when compared with cultured cells in normal serum. These studies support the notion that host derived factors operative during drug induced aplasia stimulate tumor growth and thereby, if the drugs are properly timed, increase sensitivity to cycle active agents.

Original languageEnglish (US)
Pages (from-to)1813-1816
Number of pages4
JournalCancer Research
Volume46
Issue number4
StatePublished - 1986

Fingerprint

Inbred BN Rats
Norway
Leukemia
Growth
Pharmaceutical Preparations
Cytarabine
Neoplasms
Injections
Myeloid Leukemia
Cytosine
Biological Assay
Cultured Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Drug induced host factors which stimulate growth of residual leukemia in Lewis x brown Norway F1 (LEW-BN) rats. / Burke, P. J.; Karp, Judith; Saylor, P. L.

In: Cancer Research, Vol. 46, No. 4, 1986, p. 1813-1816.

Research output: Contribution to journalArticle

@article{e7229a011b564135993e1ff8118b74f3,
title = "Drug induced host factors which stimulate growth of residual leukemia in Lewis x brown Norway F1 (LEW-BN) rats",
abstract = "Antitumor synergism occurs with two drugs in sequence when the second drug is given at the time of maximal regrowth of residual leukemia and peak humoral stimulatory activity (HSA). To determine if this enhancement relates to a host derived HSA, studies were conducted in Lewis x brown Norway F1 rats bearing brown Norway myelocytic leukemia. A significant cure rate was observed in rats treated initially with 1-β-D-arabinofuranosylcytosine and then given injections of 106 leukemia cells and treated with a second 2-day course of 1-β-D-arabinofuranosyl-cytosine in every-8-h s.c. injections in the 6-day period after the initial drug. No effect on survival of the initial drug or of the second drug given at intervals after day 6 was noted. This result is consistent with the efficacy of treatment at the time of peak HSA and tumor growth. The direct effect of HSA on tumor sensitivity to 1-β-D-arabinofuranosylcytosine was evaluated by 18-h incubations of leukemia and HSA, followed by bioassay. Increased survival and high cure rates were observed when compared with cultured cells in normal serum. These studies support the notion that host derived factors operative during drug induced aplasia stimulate tumor growth and thereby, if the drugs are properly timed, increase sensitivity to cycle active agents.",
author = "Burke, {P. J.} and Judith Karp and Saylor, {P. L.}",
year = "1986",
language = "English (US)",
volume = "46",
pages = "1813--1816",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Drug induced host factors which stimulate growth of residual leukemia in Lewis x brown Norway F1 (LEW-BN) rats

AU - Burke, P. J.

AU - Karp, Judith

AU - Saylor, P. L.

PY - 1986

Y1 - 1986

N2 - Antitumor synergism occurs with two drugs in sequence when the second drug is given at the time of maximal regrowth of residual leukemia and peak humoral stimulatory activity (HSA). To determine if this enhancement relates to a host derived HSA, studies were conducted in Lewis x brown Norway F1 rats bearing brown Norway myelocytic leukemia. A significant cure rate was observed in rats treated initially with 1-β-D-arabinofuranosylcytosine and then given injections of 106 leukemia cells and treated with a second 2-day course of 1-β-D-arabinofuranosyl-cytosine in every-8-h s.c. injections in the 6-day period after the initial drug. No effect on survival of the initial drug or of the second drug given at intervals after day 6 was noted. This result is consistent with the efficacy of treatment at the time of peak HSA and tumor growth. The direct effect of HSA on tumor sensitivity to 1-β-D-arabinofuranosylcytosine was evaluated by 18-h incubations of leukemia and HSA, followed by bioassay. Increased survival and high cure rates were observed when compared with cultured cells in normal serum. These studies support the notion that host derived factors operative during drug induced aplasia stimulate tumor growth and thereby, if the drugs are properly timed, increase sensitivity to cycle active agents.

AB - Antitumor synergism occurs with two drugs in sequence when the second drug is given at the time of maximal regrowth of residual leukemia and peak humoral stimulatory activity (HSA). To determine if this enhancement relates to a host derived HSA, studies were conducted in Lewis x brown Norway F1 rats bearing brown Norway myelocytic leukemia. A significant cure rate was observed in rats treated initially with 1-β-D-arabinofuranosylcytosine and then given injections of 106 leukemia cells and treated with a second 2-day course of 1-β-D-arabinofuranosyl-cytosine in every-8-h s.c. injections in the 6-day period after the initial drug. No effect on survival of the initial drug or of the second drug given at intervals after day 6 was noted. This result is consistent with the efficacy of treatment at the time of peak HSA and tumor growth. The direct effect of HSA on tumor sensitivity to 1-β-D-arabinofuranosylcytosine was evaluated by 18-h incubations of leukemia and HSA, followed by bioassay. Increased survival and high cure rates were observed when compared with cultured cells in normal serum. These studies support the notion that host derived factors operative during drug induced aplasia stimulate tumor growth and thereby, if the drugs are properly timed, increase sensitivity to cycle active agents.

UR - http://www.scopus.com/inward/record.url?scp=0022615176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022615176&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 1813

EP - 1816

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 4

ER -